Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

• Awaiting development
• Reference number: GID-TA11517
• Expected publication date: TBC